January 26, 2022
Article
A new orally delivered investigational therapy could help curb the costly and often recurring infection.
January 14, 2022
The results of the prospective study diverge from published retrospective studies.
January 10, 2022
Video
Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.
January 07, 2022
Ferring’s Microbiome Health Index is a diagnostic tool that may help distinguish a healthy gut microbiome from post-antibiotic dysbiosis, and could potentially identify debilitating illnesses such as C difficile infection
The single-center study suggested shoes are a common transmission route, but also hinted at a diverse web of transmission involving humans, animals, and the environment.
January 05, 2022
Fecal microbiota transplantation (FMT) is known to be an effective treatment for recurrent Clostridioides difficile infection. New research from the UVA School of Medicine reveals why.
January 04, 2022
Underweight elderly pneumonia patients were more likely to contract C difficile infection.
January 03, 2022
Matt Henn, chief scientific officer at Seres Therapeutics, discusses new ways of targeting infectious diseases and antimicrobial resistant infections.
Practical considerations for the future use of novel FMT therapy for patients with recurrent Clostridioides difficile infection.
The panel reviews phase 3 data behind SER-109, another novel FMT therapy for patients with recurrent Clostridioides difficile infection.
